Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Asset turnover

Asset turnover at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.7×0.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.5×0.0×
Amgen logo
AmgenAMGN
0.4×0.0×
AbbVie logo
AbbVieABBV
0.5×+0.1×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.1×0.0×

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

total revenue/total assets=0×

Based on trailing twelve months.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed August 11, 2025. Open the filing →

Filed
Aug 11, 2025
Fiscal quarter
Q2 FY2025
Calendar quarter
Q2 2025
Accession
0001213900-25-074281

FAQ

What is Oruka Therapeutics, Inc.'s asset turnover?
Oruka Therapeutics, Inc. (ORKA) reported asset turnover of 0× in Q2 2024.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.

Ask your AI about Oruka Therapeutics, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude